Combination of an Insulin and a GLP-1 Agonist

A pharmaceutical formulation comprising a combination of:

• (a) insulin glargine or a pharmaceutically acceptable salt thereof, and
• (b) desPro36exendin-4(1-39)-Lys6-NH2 (AVE0010) or a pharmaceutically acceptable salt thereof;
• wherein the concentration of insulin glargine is about 100 units/mL, and the concentration of AVE0010 is about 33 μg/mL;
• and
• wherein the dosage of insulin glargine is between about 15 units and about 80 units, and the dosage of AVE0010 is between about 5 μg and about 20 μg.